Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) just unveiled an update.
Cosmo Pharmaceuticals N.V. has extended its strategic production agreement with Takeda for the global supply of Mesalazine MMX 1200 mg, a medication for ulcerative colitis. This extension reinforces Cosmo’s role as a reliable partner in the pharmaceutical industry, highlighting its manufacturing capabilities and commitment to innovation and sustainability. The agreement aligns with Cosmo’s Vision 2030 strategy to expand its leadership position as a CDMO and strengthen its global partnerships.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). It designs, develops, and manufactures advanced solutions to meet critical medical needs, with a focus on improving the standard of care. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo has a global presence with branches in the USA and Italy.
Average Trading Volume: 24,934
Technical Sentiment Signal: Sell
Current Market Cap: CHF936.2M
Learn more about COPN stock on TipRanks’ Stock Analysis page.